US 12091460
Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 12091460 (Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K51/1042